Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics

• Published in: Antibodies (Basel) Vol. 8; no. 3; p. 46
• Main Authors: Douillard, Patrice, Freissmuth, Michael, Antoine, Gerhard, Thiele, Michael, Fleischanderl, Daniel, Matthiessen, Peter, Voelkel, Dirk, Kerschbaumer, Randolf J., Scheiflinger, Friedrich, Sabarth, Nicolas
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 06-09-2019; MDPI
• Subjects: aggregation; Antibodies; antibody engineering; antibody expression; Biopharmaceuticals; Chains; Chromatography; Cloning; Data analysis; Design modifications; Domains; E coli; framework; Genes; germline; Homology; Laboratories; Leukocyte migration; Libraries; Macrophage migration inhibitory factor; Manufacturability; MIF; Mutation; Optimization; Pharmacokinetics; Pharmacology; Protein engineering; Proteins; Thermal stability; United States > US; Baltimore Maryland; Germany
• ISSN: 2073-4468; 2073-4468
• DOI: 10.3390/antib8030046

Efficacy, safety, and manufacturability of therapeutic antibodies are influenced by their biopharmaceutical and biophysical properties. These properties can be optimized by library approaches or rationale protein design. Here, we employed a protein engineering approach to modify the variable domain of the light chain (VL) framework of an oxidized macrophage migration inhibitory factor (oxMIF)-specific antibody. The amendment of the antibody sequence was based on homology to human germline VL genes. Three regions or positions were identified in the VL domain—L1-4, L66, L79—and mutated independently or in combination to match the closest germline V gene. None of the mutations altered oxMIF specificity or affinity, but some variants improved thermal stability, aggregation propensity, and resulted in up to five-fold higher expression. Importantly, the improved biopharmaceutical properties translated into a superior pharmacokinetic profile of the antibody. Thus, optimization of the V domain framework can ameliorate the biophysical qualities of a therapeutic antibody candidate, and as result its manufacturability, and also has the potential to improve pharmacokinetics.